Key Takeaways
- CDMO revenue fell on API pass-through, not volume: Revenue declined because open costing passes lower API prices straight through the top line, while margins stayed protected. The CDMO share drop from 74% to 59% also reflects Sharon's consolidation.
- Jammu plant is the growth story, starting Q3: Two blocks near completion by March end, two more by May/June; commercial production begins late Q1/H1, but the P&L only sees full-quarter revenue from Q3, when the 12% GST incentive also starts pulling demand.
- Sharon acquisition already adding margin heft: Sharon brought 45-50% gross conversion margin and a regulated-market footprint; post-acquisition synergies are expected to lift that further, improving the blended profile.
- Capacity is the binding constraint in cephalosporin: Existing Baddi cephalosporin block is at 75-80% utilization with some dosage forms at 90%, while the general block sits at ~40%. Jammu directly relieves that bottleneck.
- What to watch next quarter: The pace of Jammu's customer audit conversions after commercial production starts, whether Sharon's margin improvement materializes in reported numbers, and any sign that CDMO volume growth is accelerating beneath the API price noise.
Jammu Plant: Timeline, Economics & Ramp-Up
- Construction status: Two blocks (Cephalosporin and General) in finishing phase, machines being installed, validation expected by March end. Beta-Lactam and Penem blocks are ~2 months behind, with physical completion by May/June.
- Revenue timeline: Commercial production starts late Q1 or during H1; full facility commercialized in the September quarter. The P&L shows full-quarter revenue only from Q3 (October-December).
- GST incentive mechanics: 12% incentive on approximately ₹650 crores of domestic sales, with ~50% of the benefit retained and the rest passed to customers. Management expects this fiscal benefit to pull early demand.
- Ramp-up trajectory: 5 years to reach 5x-6x asset turn (₹1,800 crores peak revenue). First year adds ~50 products, second year ~100 products, producing a geometrical revenue effect. FY26 utilization is targeted at 15-20%.
- GST threshold constraint: The ₹625 crores domestic turnover threshold must be achieved within the first 3 years of Jammu operations; carry-forward is allowed only in that window.
- Customer readiness: 25-30 products already developed with stability data for Beta-Lactam and Penem categories; existing customers have indicated business can start as soon as the facility is operational. Customer audits take 2-3 months after commercial production begins.
- Monthly cost before revenue: Q2 will carry ~₹2 crores/month in expenses with minimal revenue; Q3 is when positive operating margin begins.
Lohariwala: "So, the benefit is, like we have earlier also said that the GST benefit. So, we have, like, 12% GST incentive on approximately, say, sale of Rs 650 crores. So, we anticipate a good ramp-up, early ramp-up due to this fiscal benefit."
CDMO Business: The Revenue vs Volume Story
- Open costing explains the revenue decline: CDMO contracts operate on an open costing basis where API prices directly determine revenue. Declining API prices reduce the top line without hurting margins, which remain protected.
- Volume data was not provided: Management declined to share CDMO volume growth or gross profit/EBITDA growth during the call, saying the data was not readily available, and offered to provide it offline.
- Standalone as a proxy: Standalone EBITDA grew ~7.5% on a 9-month basis, and management pointed to standalone numbers as a reasonable proxy for CDMO volume and EBITDA trends.
- CDMO share drop is partly mechanical: The CDMO revenue share fell from 74% to 59%, but this includes the effect of Sharon's revenue being added to the consolidated top line, not just organic decline.
- Order book is short-cycle: The order book spans only 1.5-2 months; customers share yearly plans and negotiate based on current API prices, so revenue reflects spot input costs quickly.
Lohariwala: "The reason for this is, if you understand the way our business operates, for us, we work with our customers on an open costing basis. And the cost of the API directly influence the revenue itself. So, with the declining API prices, our revenues also can take a downward trajectory. However, our margins remain protected."
Sharon Acquisition: Integration & Margin Impact
- Pre-acquisition profile: Sharon had 45-50% gross conversion margin and 14-15% EBITDA pre-acquisition, with a focus on regulated markets.
- Post-acquisition synergies: Both formulation and API businesses are showing improvement; common customers and export API business are performing better. Management expects margins to improve further from the pre-acquisition baseline.
- Capacity headroom: No immediate capex planned for Sharon; debottlenecking and section-wise expansion will be considered once utilization rises another 10-15%.
- Management structure: Sharon runs independently with its own management team; group-level focus is on synergies rather than day-to-day integration.
Capacity & Utilization Across the Base
- Blended utilization at 45-50% masks wide variation: The cephalosporin block and the original 2006 unit are at 70-75% utilization, while the general block (expanded in 2021) sits at ~40%.
- Cephalosporin is the binding constraint: Existing Baddi cephalosporin block is at 75-80% overall, with some dosage forms hitting 90%. Jammu adds two more dry powder injectable lines to relieve this.
- General block has ample headroom: Dry syrup, tablet, and capsule capacity can absorb significant volume; overall utilization can rise from 45-50% to 70-75% without new capex.
- Other plants near peak: Ointments and dry powder injection are nearing peak utilization; liquid orals have already peaked. Sharon plants are showing improvement over last year.
- Target utilization: 70-75% is considered good volume utilization; peak season can reach 90-95%, lean season 50-60%.
Margins: Current State & Improvement Path
- Gross margin sensitivity: Cost pass-through is mostly complete; gross margins could move ±1 percentage point based on product mix and pricing, not further cost changes.
- Three margin drivers identified: Sharon's higher gross margin and regulated-market focus; Jammu's GST benefit with ~50% retention; and operating leverage as existing plant utilization rises toward 70-75%.
- Blended margin target: Management aspires to blended operating margins above 15% in FY25-FY26, driven by the Jammu GST benefit and better utilization in existing plants. When asked directly, the response was aspirational rather than a firm commitment.
- CCPS one-off: CCPS-related expenses of ₹1.6 crores in Q3 and ₹8.5 crores on a 9-month basis will not recur, as the CCPS was subverted in the following quarter.
Srivastava: "We would love, that would be the target we would want to go with."
Market Structure & Competitive Positioning
- Regulatory consolidation is a tailwind: The Schedule M revision (GMP at par with international standards) and rules making marketing companies equally responsible for product quality are driving consolidation from fragmented small players toward large organized players.
- Differentiation was not specified: When asked about competitive differentiation versus other large CDMO players, management answered generically about market consolidation and customer decision factors (product availability, dossier, price) without naming Innova's specific advantage.
- Regulated market expansion: The company is looking to expand to the UK and Canada by broadening its product range. A DSIR-approved R&D center is already established, and a new R&D center is being set up in Panchkula, Haryana.
Lohariwala: "So, all the large players will be benefit from these issues."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Jammu commercial production start | Two blocks validation-ready by March end; full facility commercialized | September quarter (Q2 FY25) |
| Jammu P&L revenue contribution | Full-quarter revenues visible | Q3 FY25 (October-December) |
| Jammu peak revenue | 5x-6x asset turn (~₹1,800 crores) | Within 5 years of start |
| Jammu FY26 utilization | 15-20% | FY26 |
| GST threshold achievement | ₹625 crores domestic turnover | Within first 3 years of Jammu operations |
| Blended operating margin | Above 15% | FY25-FY26 (aspirational, not firm) |
| No major capex | Focus on scaling Sharon and Jammu | Next 2-3 years |
| Sharon and Jammu scale-up | Running on autopilot | Next 18 months |
| CCPS expenses | ₹1.6 cr/quarter and ₹8.5 cr/9-month charges cease | Already ceased (subverted post-Q3) |
| Interest cost | Only Jammu project debt of ₹235 cr at effective 2.5% | Going forward |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue from operations | ₹302.5 cr, +25% YoY |
| Revenue from operations (9M FY24) | ₹818.7 cr, +19.4% YoY |
| EBITDA | ₹47 cr, +27% YoY |
| EBITDA margin | 15.5% |
| EBITDA (9M FY24) | ₹123.2 cr, vs ₹93.4 cr in 9M FY23 |
| EBITDA margin (9M FY24) | 15% |
| Profit after tax | ₹25 cr, +28% YoY; includes ₹1.6 cr CCPS finance cost impact |
| Profit after tax (9M FY24) | ₹65.6 cr, +29.4% YoY |
| CDMO revenue contribution | 55% of total revenue |
| Domestic branded generic contribution | 17% of total revenue |
| International branded generic contribution | 12% of total revenue |
| Sharon contribution | 16% of total revenue |
| Overall exports share | 24%, vs 10% in Q3 FY23 |
| CDMO revenue (9M FY24) | ₹484.2 cr |
| Capacity utilization (9M FY24) | 45% to 50% blended |
| Cephalosporin capacity utilization | 70% to 75% |
| General block capacity utilization | ~40% |
| Order book (ex-Sharon) | ~₹140–₹150 cr, representing 1.5 months |
| CCPS one-off finance cost impact | ₹1.6 cr in Q3; ₹8.5 cr on 9M basis |
| Jammu project cost | ~₹350 cr |
| Jammu project debt | ₹235 cr, effective interest cost 2.5% after 6% subvention |
| Jammu peak revenue potential | ~₹1,800 cr, based on 5x–6x asset turnover |
| Jammu soft running cost (pre-revenue) | ~₹2 cr per month including depreciation |
| IPO net proceeds deployed | ₹231 cr, 100% of FY24 deployment target |
| Interest savings expected (full-year FY25) | ~₹18 cr to ₹20 cr |
| Sharon FY23 revenue | ~₹192 cr, at ~50% capacity utilization |
| Sharon gross conversion margin | 45% to 50% |
| GST benefit on Jammu domestic turnover | 12% reimbursement on ~₹625 cr turnover for full annual benefit of ₹75 cr |
| Cephalosporin revenue contribution | ~22% of total |
| Cephalosporin incremental peak revenue from Jammu | ₹300–₹400 cr over 3–4 years |
| Univentis domestic branded generic business | ~₹200 cr expected this year |
| Active international registrations | 189 (16 subject to renewal); 200+ fresh applications in process |
| In-process product dossiers for exports | 41 |
| CDMO customers (9M FY24) | more than 180 |